Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
| Autor: | Carmona-Bayonas, Alberto, Jiménez-Fonseca, Paula, Lamarca, Ángela, Barriuso, Jorge, Castaño, Ángel, Benavent, Marta, Alonso, Vicente, Riesco-Martínez, María del Carmen, Alonso-Gordoa, Teresa, Custodio, Ana, Sánchez Cánovas, Manuel, Hernando Cubero, Jorge, López, Carlos, Lacasta, Adelaida, Fernández Montes, Ana, Marazuela, Mónica, Crespo, Guillermo, Escudero, Pilar, Diaz, José Ángel, Feliciangeli, Eduardo, Gallego, Javier, Llanos, Marta, Segura, Ángel, Vilardell, Felip, Percovich, Juan Carlos, Grande, Enrique, Capdevila Castillón, Jaume, Valle, Juan W., García-Carbonero, Rocío, Universitat Autònoma de Barcelona |
|---|---|
| Přispěvatelé: | LEO Pharma, Ipsen, Pfizer, Roche, Amgen, Merck & Co, Merck Sharp & Dohme, AstraZeneca, Sanofi, Bayer, Eisai, Celgene, Novartis, Advanced Accelerator Applications, Bristol-Myers Squibb, UAM. Departamento de Medicina, Novartis Farmaceútica |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Male Cancer Research Octreotide Neuroendocrine tumors Lanreotide THERAPY Cohort Studies chemistry.chemical_compound 0302 clinical medicine PROGNOSTIC-FACTORS EVEROLIMUS Gastrointestinal Cancer prognostic model Manchester Cancer Research Centre ORIGINAL REPORTS somatostatin analogs Progression-Free Survival Neuroendocrine Tumors 030220 oncology & carcinogenesis Female lanreotide Somatostatin medicine.drug Cohort study NEOPLASMS Adult medicine.medical_specialty Adolescent Medicina SUNITINIB nomogram 03 medical and health sciences Young Adult Internal medicine medicine Humans Progression-free survival Survival analysis Retrospective Studies business.industry ResearchInstitutes_Networks_Beacons/mcrc Retrospective cohort study Nomogram medicine.disease Survival Analysis Hormones MODEL 030104 developmental biology chemistry REGISTRY business octreotide |
| Zdroj: | JOURNAL OF CLINICAL ONCOLOGY r-FISABIO. Repositorio Institucional de Producción Científica instname Digital.CSIC. Repositorio Institucional del CSIC Biblos-e Archivo. Repositorio Institucional de la UAM Carmona-bayonas, A, Jiménez-fonseca, P, Lamarca, Á, Barriuso, J, Castaño, Á, Benavent, M, Alonso, V, Riesco-martínez, M D C, Alonso-gordoa, T, Custodio, A, Sánchez Cánovas, M, Hernando Cubero, J, López, C, Lacasta, A, Fernández Montes, A, Marazuela, M, Crespo, G, Escudero, P, Diaz, J Á, Feliciangeli, E, Gallego, J, Llanos, M, Segura, Á, Vilardell, F, Percovich, J C, Grande, E, Capdevila, J, Valle, J W & García-carbonero, R 2019, ' Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study ', Journal of Clinical Oncology, pp. JCO.19.00980 . https://doi.org/10.1200/JCO.19.00980 Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) Journal of Clinical Oncology Repisalud Instituto de Salud Carlos III (ISCIII) r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe |
| ISSN: | 0732-183X |
| DOI: | 10.1200/JCO.19.00980 |
| Popis: | [Purpose] Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current study was to develop and validate a progression-free survival (PFS) prediction model in SSA-treated patients. [Patient and methods] We extracted data from the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE). Patient eligibility criteria included GEP primary, Ki-67 of 20% or less, and first-line SSA monotherapy for advanced disease. An accelerated failure time model was developed to predict PFS, which was represented as a nomogram and an online calculator. The nomogram was externally validated in an independent series of consecutive eligible patients (The Christie NHS Foundation Trust, Manchester, United Kingdom). [Results] We recruited 535 patients (R-GETNE, n = 438; Manchester, n = 97). Median PFS and overall survival in the derivation cohort were 28.7 (95% CI, 23.8 to 31.1) and 85.9 months (95% CI, 71.5 to 96.7 months), respectively. Nine covariates significantly associated with PFS were primary tumor location, Ki-67 percentage, neutrophil-to-lymphocyte ratio, alkaline phosphatase, extent of liver involvement, presence of bone and peritoneal metastases, documented progression status, and the presence of symptoms when initiating SSA. The GETNE-TRASGU (Treated With Analog of Somatostatin in Gastroenteropancreatic and Unknown Primary NETs) model demonstrated suitable calibration, as well as fair discrimination ability with a C-index value of 0.714 (95% CI, 0.680 to 0.747) and 0.732 (95% CI, 0.658 to 0.806) in the derivation and validation series, respectively. [Conclusion] The GETNE-TRASGU evidence-based prognostic tool stratifies patients with GEP neuroendocrine tumors receiving SSA treatment according to their estimated PFS. This nomogram may be useful when stratifying patients with neuroendocrine tumors in future trials. Furthermore, it could be a valuable tool for making treatment decisions in daily clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|